* Q3 loss $0.12/shr vs loss $0.19/shr
* Revenue down 33.7 percent at $5.7 mln (In U.S. dollars unless noted)
TORONTO, Nov 9 (Reuters) - Drugmaker AEterna Zentaris AEZ.TO posted a narrower quarterly loss on Tuesday, citing lower expenses, which offset lower revenues and higher foreign exchange losses.
Quebec City-based AEterna, which specializes in developing drugs for treating cancer, said it had a third quarter loss of $10.1 million, or 12 cents a share, for the three months ended Sept. 30. That compared with a loss of $11.3 million, or 19 cents a share, a year earlier.
Revenue fell 33.7 percent to $5.7 million.
AEterna shares were down 0.8 percent at C$1.23 on the Toronto Stock Exchange early Tuesday afternoon.
$1=$1.00 Canadian Reporting by Solarina Ho; editing by Rob Wilson